Plasmodium berghei circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice

Table 1 Effects of OML-PbMSP1 immunization against P. berghei merozoite challenge

Immunization	Antibody titration*		Infected/total [l^st+2^ndtrials]	Survival*	Protection^†
	IgGl	IgG2a	(Number)	(Day)	(%)
OML-PbMSP1	11636 ± 5593^††	2182 ± 1604^††	11/11 [(5/5) + (6/6)]	19.1 ± 10.9	0
PbMSP1	1333 ± 413	283 ± 132	6/6	14.3 ± 6.7	0
OML-PBS	0	0	11/11 [(5/5) + (6/6)]	11.3 ± 5.3	0
None	0	0	11/11 [(5/5) + (6/6)]	11.8 ± 5.2	0

*Antigen-specific 1gG1 and IgG2a detected by ELISA with recombinant PbMSP1 at 14 days after the last boost. Each value represents the mean titer of antibody ± SD per mouse group.
*Each value represents the average survival day ± SD per mouse group.
^†Mice were scored as protected when parasitemia was not observed over a 30-day period.
^††Indicates statistically significant differences between the antibody titers of OML-PbMSP1-immunized mice and those of the corresponding mice immunized with naked antigen.
Results represent pooled data of two independent experiments.

ISSN: 1475-2875